Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 2, 2009

Researchers Pinpoint Gene Variations in Ovarian Cancer Patients with Better Prognosis

  • Scientists led by the Queensland Institute of Medical Research (QIMR) found an association between a combination of ABCB1 gene variations and a better prognosis for women with ovarian cancer.

    The ABCB1 gene is responsible for the body’s ability to transport a broad range of anticancer drugs, explain the investigators, who reported their findings in Clinical Cancer Research. They analysed variations of these genes by looking at progression-free and overall survival in 309 women with ovarian cancer who were treated with chemotherapy drugs.

    The found that women who had minimal residual disease and were carrying a particular combination of ABCB1 gene variations took a much longer time to relapse following treatment.

    Further research is needed to understand the role of different chemotherapy drugs as well as to see if this gene combination is linked to overall survival, according to Georgia Chenevix-Trench, Ph.D., head of the cancer and cell biology laboratory at QIMR.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »